FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021073739> ?p ?o ?g. }

• W2021073739 endingPage "1090" @default.
• W2021073739 startingPage "1081" @default.
• W2021073739 abstract "ObjectivesIn 2012, the National Institute for Health and Care Excellence assessed dasatinib, nilotinib, and standard-dose imatinib as first-line treatment of chronic phase chronic myelogenous leukemia (CML). Licensing of these alternative treatments was based on randomized controlled trials assessing complete cytogenetic response (CCyR) and major molecular response (MMR) at 12 months as primary end points. We use this case study to illustrate the validation of CCyR and MMR as surrogate outcomes for overall survival in CML and how this evidence was used to inform National Institute for Health and Care Excellence’s recommendation on the public funding of these first-line treatments for CML.MethodsWe undertook a systematic review and meta-analysis to quantify the association between CCyR and MMR at 12 months and overall survival in patients with chronic phase CML. We estimated life expectancy by extrapolating long-term survival from the weighted overall survival stratified according to the achievement of CCyR and MMR.ResultsFive studies provided data on the observational association between CCyR or MMR and overall survival. Based on the pooled association between CCyR and MMR and overall survival, our modeling showed comparable predicted mean duration of survival (21–23 years) following first-line treatment with imatinib, dasatinib, or nilotinib.ConclusionsThis case study illustrates the consideration of surrogate outcome evidence in health technology assessment. Although it is often recommended that the acceptance of surrogate outcomes be based on randomized controlled trial data demonstrating an association between the treatment effect on both the surrogate outcome and the final outcome, this case study shows that policymakers may be willing to accept a lower level of evidence (i.e., observational association)." @default.
• W2021073739 created "2016-06-24" @default.
• W2021073739 creator A5003038977 @default.
• W2021073739 creator A5008052793 @default.
• W2021073739 creator A5019829350 @default.
• W2021073739 creator A5037428320 @default.
• W2021073739 creator A5056116956 @default.
• W2021073739 creator A5080301974 @default.
• W2021073739 creator A5082727271 @default.
• W2021073739 date "2013-09-01" @default.
• W2021073739 modified "2023-10-18" @default.
• W2021073739 title "Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence" @default.
• W2021073739 cites W1964280661 @default.
• W2021073739 cites W1964554673 @default.
• W2021073739 cites W1965870971 @default.
• W2021073739 cites W1966282229 @default.
• W2021073739 cites W1967031426 @default.
• W2021073739 cites W1971895240 @default.
• W2021073739 cites W1971940453 @default.
• W2021073739 cites W1975164251 @default.
• W2021073739 cites W1984617193 @default.
• W2021073739 cites W1993756686 @default.
• W2021073739 cites W2001289393 @default.
• W2021073739 cites W2006917576 @default.
• W2021073739 cites W2009746825 @default.
• W2021073739 cites W2012828386 @default.
• W2021073739 cites W2013239206 @default.
• W2021073739 cites W2016656445 @default.
• W2021073739 cites W2020018978 @default.
• W2021073739 cites W2021648831 @default.
• W2021073739 cites W2027610952 @default.
• W2021073739 cites W2028959752 @default.
• W2021073739 cites W2057206328 @default.
• W2021073739 cites W2057827171 @default.
• W2021073739 cites W2058576674 @default.
• W2021073739 cites W2061351198 @default.
• W2021073739 cites W2061440903 @default.
• W2021073739 cites W2068977368 @default.
• W2021073739 cites W2070067474 @default.
• W2021073739 cites W2070683532 @default.
• W2021073739 cites W2072834954 @default.
• W2021073739 cites W2076500257 @default.
• W2021073739 cites W2079517811 @default.
• W2021073739 cites W2080125373 @default.
• W2021073739 cites W2084877846 @default.
• W2021073739 cites W2091005492 @default.
• W2021073739 cites W2096285574 @default.
• W2021073739 cites W2097799776 @default.
• W2021073739 cites W2103072940 @default.
• W2021073739 cites W2113111562 @default.
• W2021073739 cites W2120959053 @default.
• W2021073739 cites W2126426045 @default.
• W2021073739 cites W2128738046 @default.
• W2021073739 cites W2132150750 @default.
• W2021073739 cites W2143939343 @default.
• W2021073739 cites W2146658081 @default.
• W2021073739 cites W2156098321 @default.
• W2021073739 cites W2158884958 @default.
• W2021073739 cites W2162525969 @default.
• W2021073739 cites W2164090407 @default.
• W2021073739 cites W2166641737 @default.
• W2021073739 cites W2166654361 @default.
• W2021073739 cites W2169561770 @default.
• W2021073739 cites W2337277825 @default.
• W2021073739 cites W2991792334 @default.
• W2021073739 cites W4246151774 @default.
• W2021073739 cites W2170022293 @default.
• W2021073739 doi "https://doi.org/10.1016/j.jval.2013.07.004" @default.
• W2021073739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24041359" @default.
• W2021073739 hasPublicationYear "2013" @default.
• W2021073739 type Work @default.
• W2021073739 sameAs 2021073739 @default.
• W2021073739 citedByCount "20" @default.
• W2021073739 countsByYear W20210737392014 @default.
• W2021073739 countsByYear W20210737392015 @default.
• W2021073739 countsByYear W20210737392016 @default.
• W2021073739 countsByYear W20210737392017 @default.
• W2021073739 countsByYear W20210737392018 @default.
• W2021073739 countsByYear W20210737392019 @default.
• W2021073739 countsByYear W20210737392020 @default.
• W2021073739 countsByYear W20210737392022 @default.
• W2021073739 countsByYear W20210737392023 @default.
• W2021073739 crossrefType "journal-article" @default.
• W2021073739 hasAuthorship W2021073739A5003038977 @default.
• W2021073739 hasAuthorship W2021073739A5008052793 @default.
• W2021073739 hasAuthorship W2021073739A5019829350 @default.
• W2021073739 hasAuthorship W2021073739A5037428320 @default.
• W2021073739 hasAuthorship W2021073739A5056116956 @default.
• W2021073739 hasAuthorship W2021073739A5080301974 @default.
• W2021073739 hasAuthorship W2021073739A5082727271 @default.
• W2021073739 hasBestOaLocation W20210737391 @default.
• W2021073739 hasConcept C126322002 @default.
• W2021073739 hasConcept C141341695 @default.
• W2021073739 hasConcept C143998085 @default.
• W2021073739 hasConcept C168563851 @default.
• W2021073739 hasConcept C2776960273 @default.
• W2021073739 hasConcept C2777413986 @default.
• W2021073739 hasConcept C2777583451 @default.

• next